<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470533</url>
  </required_header>
  <id_info>
    <org_study_id>NL51318.078.14</org_study_id>
    <nct_id>NCT02470533</nct_id>
  </id_info>
  <brief_title>Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma</brief_title>
  <acronym>TRENDY</acronym>
  <official_title>Transarterial Chemoembolization With Drug-Eluting Beads (Standard Arm) Versus Stereotactic Body Radiation Therapy (Experimental Arm) for Hepatocellular Carcinoma: A Multicenter Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University of Amsterdam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastro Clinic, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:&#xD;
&#xD;
      This study will compare head to head in patients with hepatocellular carcinoma (HCC)&#xD;
      ineligible for surgery or radiofrequency ablation, the standard treatment arm, transarterial&#xD;
      chemoembolization with drug-eluting beads (TACE-DEB), with the experimental arm, stereotactic&#xD;
      body radiation therapy (SBRT). The investigators hypothesis is that the time to progression&#xD;
      is more favorable after SBRT than after TACE-DEB. The expected time to include the required&#xD;
      patients for this trial will be four years.&#xD;
&#xD;
      To the best of the investigators knowledge this study will be the first in the world that&#xD;
      will compare both techniques in a randomized trial.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To assess the time to progression after TACE-DEB and after SBRT in a comparable population of&#xD;
      patients diagnosed with HCC.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Randomized, prospective, open-label, and phase II study.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients diagnosed with HCC, Child-Pugh grade A, one to three tumors, cumulative diameter ≤&#xD;
      6cm, and ≥ 18 years old.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Patients with HCC will be randomized to receive the standard treatment, TACE-DEB loaded with&#xD;
      doxorubicin or the experimental arm, SBRT.&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
      The primary endpoint of this study will be time to progression, defined as time from&#xD;
      randomization to radiological progression.&#xD;
&#xD;
      Secondary endpoints will be:&#xD;
&#xD;
        -  Time to local recurrence&#xD;
&#xD;
        -  Response rate (complete and partial response)&#xD;
&#xD;
        -  Overall survival&#xD;
&#xD;
        -  Toxicity&#xD;
&#xD;
        -  Quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary liver cancer, particularly hepatocellular carcinoma (HCC) is a major health problem.&#xD;
      Curative therapies for HCC are considered hepatic resection, liver transplantation and&#xD;
      radiofrequency ablation (RFA). Hepatic resection is preferred for patients with limited&#xD;
      disease, non-cirrhotic livers or selected patients with Child-Pugh A cirrhosis. Unlike&#xD;
      resection, liver transplantation treats the tumor and the underlying cirrhosis present in the&#xD;
      liver. Candidates for liver transplantation are preferably those with cirrhosis and tumors&#xD;
      that comply with the Milan criteria (single tumor &lt;5cm or 1-3 tumors each of ≤ 3cm). Because&#xD;
      most patients are not amenable to resection or liver transplantation, RFA has emerged as an&#xD;
      effective treatment option. RFA is limited by the location of the tumor in the liver and by&#xD;
      the tumor size with best results after RFA achieved for tumors ≤3cm. For patients that are&#xD;
      not eligible for RFA due to large or multifocal tumors, transarterial chemoembolization with&#xD;
      drug-eluting beads (TACE-DEB) is the preferred treatment.&#xD;
&#xD;
      Stereotactic body radiation therapy (SBRT) delivers a highly effective dose of irradiation to&#xD;
      the tumor while maximally avoiding dose delivery to surrounding healthy structures. SBRT is&#xD;
      offered as an ablative local treatment with reported high percentages of complete and partial&#xD;
      responses with limited toxicity.&#xD;
&#xD;
      An international expert committee on HCC has recommended time to progression (TTP) as primary&#xD;
      endpoint for phase II randomized trials. Although data is scarce the best published median&#xD;
      TTP after TACE-DEB was 16 months and after SBRT 36.5months in a more or less comparable&#xD;
      patient population (Barcelona Clinic Liver Cancer stage system A-C).&#xD;
&#xD;
      The present study will include patients not eligible for resection or RFA. Patients may be&#xD;
      eligible for bridging or for down staging to transplantation. Well compensated liver&#xD;
      cirrhosis (Child-Pugh A) and disease confined to the liver (one to three tumors cumulative&#xD;
      diameter ≤ 6cm) is required. To our knowledge this trial will be the first in the world to&#xD;
      compare TACE-DEB and SBRT. This trial may have a big impact on the control of the disease and&#xD;
      may contribute to change the standard of care from a palliative to a more radical/curative&#xD;
      intention in this patient population&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual&#xD;
  </why_stopped>
  <start_date type="Actual">April 30, 2015</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to local recurrence</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>4 years</time_frame>
    <description>Common toxicity criteria v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>4 years</time_frame>
    <description>EORTC Quality of life forms C-30 and HCC-18, Quality of life form Euro QoL5D</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>Transarterial chemoembolization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemoembolization will be performed through a transarterial route delivering drug eluting beads, i.e. hydrogel-based microspheres (Biocompatibles UK, Ltd, HepaSphere Biosphere Medical) loaded with the chemotherapeutic agent doxorubicin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic body radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risk-adapted dose prescription for delivering the highest possible tumor dose not exceeding the maximum dose in 6 fractions of 8-9 Gy, while hepatic normal tissue complication probability (NTCP) &lt; of 5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>6 fractions of 8-9Gy</description>
    <arm_group_label>Stereotactic body radiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>chemoembolization</intervention_name>
    <description>Up to 4 sessions</description>
    <arm_group_label>Transarterial chemoembolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with HCC Patients can be included if they require treatment prior&#xD;
             to liver transplantation.&#xD;
&#xD;
          -  Barcelona Clinic Liver Cancer Stage System class A-B&#xD;
&#xD;
          -  One to three tumors of maximum cumulative diameter ≤ 6 cm measured in all 3 axes.&#xD;
&#xD;
          -  Measurable disease to be selected as a target on CT/MRI-scan, according to mRECIST&#xD;
             criteria for HCC within 6 weeks prior to randomization (≥ 1cm at least in one&#xD;
             dimension, suitable for repeated measurement, and arterial enhancement) [44].&#xD;
&#xD;
          -  Tumor visibility on CT&#xD;
&#xD;
          -  Child-Pugh A cirrhosis&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Albumin&gt; 28 g/l, bilirubin &lt; 50 µmol/l, INR &lt; 2.3, AST/ALT &lt; 5 times ULN, within 6&#xD;
             weeks prior to randomization&#xD;
&#xD;
          -  Platelets will be preferably ≥ 50x10E9/ l (if not, thrombocytes transfusion is allowed&#xD;
             to ensure a safe procedure at the discretion of the interventional radiologist and&#xD;
             gastroenterologist). Leukocytes &gt; 1.5x10E9/l, Hb &gt; 6 mmol/l, within 6 weeks prior to&#xD;
             randomization&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Willing and able to comply to the follow-up schedule&#xD;
&#xD;
          -  Planned to start treatment within 6 weeks from randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eligibility for resection or RFA&#xD;
&#xD;
          -  More than three tumors in the liver&#xD;
&#xD;
          -  Ascites&#xD;
&#xD;
          -  Any signs of acute viral or non-viral hepatitis&#xD;
&#xD;
          -  Encephalopathy&#xD;
&#xD;
          -  Vascular tumor invasion (contact with the vessel will not be considered&#xD;
             contraindication).&#xD;
&#xD;
          -  Previous radiotherapy to the liver&#xD;
&#xD;
          -  Known current pregnancy&#xD;
&#xD;
          -  Distance from the tumor to the esophagus, stomach, duodenum, small bowel or large&#xD;
             bowel &lt; 0.5 cm on CT or on MRI (randomization imaging). Depending on the SBRT&#xD;
             technique used, the minimum acceptable distance may vary and be larger for one&#xD;
             technique compared to the other&#xD;
&#xD;
          -  Uncontrolled portal hypertension (high bleeding risk). If gastroscopy has been&#xD;
             performed, untreated esophageal varices grade III or IV.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alejandra Mendez Romero, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adriaan Moelker, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UH Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>ZH</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU MC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastro</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Alejandra Mendez Romero</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

